39th week of 2009 patent applcation highlights part 45 |
Patent application number | Title | Published |
20090239824 | HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE - Compositions and methods of use of borole derivatives, including benzoxaboroles, benzazaboroles and benzthiaboroles, as therapeutic agents for treatment of diseases caused by bacteria or viruses are disclosed, as well as methods for synthesis of said agents and compositions thereof. | 2009-09-24 |
20090239825 | MULTI-CAROTENOIDS COMPOSITIONS AND USES THEREFOR - Methods for ameliorating the effects of benign prostate hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) in men, comprising orally administering an effective amount of multi-carotenoids compositions. Multi-carotenoids composition for oral administration comprising about 71% by weight, of a tomato extract containing therein about 2% to 10% by weight of lycopene, about 0.25% to 2% by weight of phytoene, and about 0.2% to 2% by weight of phytofluene, and about 29% by weight, of a suitable encapsulating matrix. A suitable encapsulating matrix is an edible oil exemplified by soya oil, pumpkin seed oil, grape-seed oil and the like. The tomato extract may additionally comprise one or more of at least one carotene selected from the group comprising β-carotene, γ-carotene, and δ-carotene, a phytosterol, a tocopheral and a phospholipid. Use of multi-carotenoids compositions for the treatment of urinary tract malfunctions including benign prostate hyperplasia and lower urinary tract symptoms. | 2009-09-24 |
20090239826 | COMPOSITIONS AND METHODS FOR THE REGULATION OF HOMOCYSTEINE LEVELS WITHIN THE BODY - Described herein is a method for reducing levels of the harmful metabolic waste product of S-adenosylmethionine (SAMe), homocysteine, and provide vitamin and other nutritional co-factors that reduce the production of homocysteine and either re-methylate homocysteine back to S-adenosylmethionine, or facilitate its conversion downstream to cystathione. The method of the invention may be achieved by administering 5-methyl tetrahydrofolate, methylcobalamin, and one or more compounds selected from the group consisting of betaine, pyridoxal-5-phosphate, N-acetyl-cysteine, and other cofactors. | 2009-09-24 |
20090239827 | COMPOUNDS HAVING LIPID LOWERING PROPERTIES - There is provided a therapy for lowering the blood levels of a lipid selected from the group comprising LDL cholesterol, triglycerides, overall cholesterol and mixtures thereof, the therapy comprising the step of administering an effective amount of one or more phosphate derivatives of one or more electron transfer agents. | 2009-09-24 |
20090239828 | Adhesive preparation - The present invention provides an adhesive preparation having a plaster layer disposed on a support, the adhesive preparation comprising at least one active ingredient selected from the group consisting of a bisphosphonic acid derivative, its salt thereof and a hydrate of either of the bisphosphonic acid derivative or the salt, a solubilizer for the active ingredient, propylene glycol, a hydrogenated terpene resin, an adhesive base, and a softening agent in the plaster layer. | 2009-09-24 |
20090239829 | THIOARYL SUBSTITUTED INHIBITORS OF ZINC PROTEASES AND THEIR USE - There are described compounds having the general formula (I) below and their pharmaceutically acceptable salts thereof, wherein E, X, m, q, R | 2009-09-24 |
20090239830 | Treatment of viral infections by modulation of host cell metabolic pathways - Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated. | 2009-09-24 |
20090239831 | Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis - The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. The invention also relates to methods of reducing the likelihood of a patient at risk for non-alcoholic fatty liver diseases (NAFLD), including non-alcoholic steatohepatitis (NASH), or treating NAFLD or NASH including primary NASH, NASH secondary to liver transplantation (NASH post-liver transplantation) or cirrhosis represent alternative aspects of the present invention. | 2009-09-24 |
20090239832 | DRUGS FOR CHRONIC PAIN - The present invention relates to nitrooxyderivatives or salts thereof having the following general formula (I): | 2009-09-24 |
20090239833 | ENHANCEMENT OF ACTIVITY AND/OR DURATION OF ACTION OF SOFT ANTI-INFLAMMATORY STEROIDS FOR TOPICAL OR OTHER LOCAL APPLICATION - Methods and compositions for enhancing the activity and/or duration of action of loteprednol etabonate and other soft anti-inflammatory steroids of the haloalkyl 17α-alkoxycarbonyloxy-11β-hydroxyandrost-4-en-3-one-17β-carboxylate type and the corresponding Δ | 2009-09-24 |
20090239834 | MCC-257 MODULATION OF NEUROGENESIS - The disclosure provides methods and a composition for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis by use of (5-acetamido-N-(5alpha-cholestan-3alpha-yl)-3,5-dideoxy-2-O-methyl-D-glycero-alpha-D-galacto-non-2-ulopyranosonamide(MCC-257). The disclosure also includes methods and a composition for stimulating or activating the formation of new nerve cells based on the application of MCC-257 | 2009-09-24 |
20090239835 | STABILIZATION OF GLUCOCORTICOID ESTERS WITH ACIDS - The invention relates to nonaqueous pharmaceutical preparations comprising a glucocorticoid ester and an acid, and to the stabilization of glucocorticoid esters in such preparations by acids. | 2009-09-24 |
20090239836 | Multifunctional Ophthalmic Compositions - An multifunctional ophthalmic composition includes a nonionic oxygen-containing polymer and a surfactant. The composition can be used to treat or control ophthalmic diseases, conditions, or disorders. The composition can be a drug delivery vehicle for medicaments having low solubility in water. | 2009-09-24 |
20090239837 | CHOLESTEROL-PRODUCING YEAST STRAINS AND USES THEREOF - The invention concerns the production of cholesterol in organisms of the Fungi kingdom. More particularly, the invention concerns genetically modified Fungus independently producing cholesterol from a simple carbon source. The invention also concerns the use of the inventive Fungus for producing non-marked and marked cholesterol. | 2009-09-24 |
20090239838 | PYRROLOTRIAZINE KINASE INHIBITORS - The invention provides compounds of formula I | 2009-09-24 |
20090239839 | RECEPTOR ANTAGONIST - An agent for modulating the function of an RFRP receptor, characterized by containing either a compound represented by the formula (I) | 2009-09-24 |
20090239840 | AMINO SUBSTITUTED DIARYL[a,d]CYCLOHEPTENE ANALOGS AS MUSCARINIC AGONISTS AND METHODS OF TREATMENT OF NEUROPSYCHIATRIC DISORDERS - Disclosed herein are analogs of clozapine and pharmaceutically acceptable salts, esters, amides, or prodrugs thereof; methods of synthesizing the analogs; and methods of using the analogs for treating neuorpsychiatric disorders. In some embodiments, the analogs are amino substituted diaryl[a,d]cycloheptenes. | 2009-09-24 |
20090239841 | Diaryl Ureas as CB1 Antagonists - Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies and various in vitro assays. | 2009-09-24 |
20090239842 | Solutions containing epinastin - Topically administered aqueous solutions containing epinastin, optionally in the form of its racemate or its enantiomers and optionally in the form of the pharmacologically acceptable acid addition salts thereof. | 2009-09-24 |
20090239843 | Bridged diazepan orexin receptor antagonists - The present invention is directed to bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 2009-09-24 |
20090239844 | ACE INHIBITOR-VASOPRESSIN ANTAGONIST COMBINATIONS - Combinations of ACE inhibitors and vasopressin antagonists are useful to slow and reverse the process of ventricular dilation, and CHF in mammals. | 2009-09-24 |
20090239845 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS - Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein Z, R | 2009-09-24 |
20090239846 | Novel Compounds - Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors. | 2009-09-24 |
20090239847 | Organic compounds - The present invention concerns a compound of formula (I) | 2009-09-24 |
20090239848 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE - The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds. | 2009-09-24 |
20090239849 | Aryl-Fused Spirocyclic Compounds - The present invention relates to a novel class of aryl-fused spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo. | 2009-09-24 |
20090239850 | Kinase protein binding inhibitors - The invention relates to protein binding inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including cell proliferative disorders, especially cancer. | 2009-09-24 |
20090239851 | Benzothiazinone Derivatives and their Use as Antibacterial Agents - The present invention relates to novel benzothiazin derivatives and their use as antibacterial agents in infectious diseases of mammals (humans and animals) caused by bacteria, especially diseases like tuberculosis (TB) and leprosy caused by mycobacteria. | 2009-09-24 |
20090239852 | USE OF OXICAM COMPOUNDS - Methods of treating and/or preventing arteriosclerosis are disclosed. In certain methods, a composition containing at least one lornoxicam or lornoxicam analogue that inhibits cyclooxygenase 1 and cyclooxygenase 2 (COX 1 and COX 2), cannot cross the blood/brain barrier under physiological conditions, and reduces the prostaglandin E2-induced induction of the amyloid precursor protein (APP) is administered to a subject to treat and/or prevent arteriosclerosis in the subject. | 2009-09-24 |
20090239853 | Fused heterocycle derivative - A fused heterocycle derivative represented by the general formula (I): | 2009-09-24 |
20090239854 | Tetracyclic compounds - This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2009-09-24 |
20090239855 | Rapamycin Analogues and the Uses Thereof in the Treatment of Neurological, Proliferative, and Inflammatory Disorders - The present invention provides for methods of treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders using compounds of the following structure: | 2009-09-24 |
20090239856 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors - A method of activating PPAR receptors in a subject, said method comprising administering to said subject an effective PPAR receptor activating amount of a pyrrolopyridine compound corresponding to formula (I): | 2009-09-24 |
20090239857 | TRIAMINE DERIVATIVE - An object of the present invention is to provide a novel compound which has a potent inhibitory effect on FXa and exhibits an excellent antithrombotic effect when orally administered. The present invention provides a compound represented by the following general formula (1): | 2009-09-24 |
20090239858 | THERAPEUTIC AMIDES - Compounds comprising | 2009-09-24 |
20090239859 | PROTEIN KINASE MODULATORS - The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules. | 2009-09-24 |
20090239860 | NOVEL BENZOFURAN DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USES OF THESE - The present invention provides compounds represented by general formula (I): | 2009-09-24 |
20090239861 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS - A quinazoline derivative of the Formula I: | 2009-09-24 |
20090239862 | Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators - Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1, such as obesity, and diabetes. | 2009-09-24 |
20090239863 | 1-ARYL-OR 1- ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS - The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor. | 2009-09-24 |
20090239864 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS - A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: | 2009-09-24 |
20090239865 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES - Dibenzyl amine compounds and derivatives, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans. | 2009-09-24 |
20090239866 | PEPTIDE DEFORMYLASE INHIBITORS - Novel PDF inhibitors and novel methods for their use are provided. | 2009-09-24 |
20090239867 | THERAPEUTIC SUBSTITUTED GAMMA LACTAMS - Disclosed herein is a compound comprising | 2009-09-24 |
20090239868 | INHIBITOR OF PAI-1 PRODUCTION - The compound represented by the following general formula (I) has an inhibitory activity on PAI-1 production; | 2009-09-24 |
20090239869 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES - Therapeutic compounds are disclosed herein. Methods, compositions, and medicaments related thereto are also disclosed. The compounds described herein are used to treat ocular conditions, bowel disease and baldness. | 2009-09-24 |
20090239870 | Spirohydantoin Aryl Cgrp Receptor Antagonists - Compounds of formula I: | 2009-09-24 |
20090239871 | SOLUBILIZED TOPOISOMERASE POISONS - The invention provides compounds of formula I: | 2009-09-24 |
20090239872 | TREATMENT OF MESOTHELIOMA - The present invention relates to a method of treating a warm-blooded animal, especially a human, having mesothelioma, especially malignant mesothelioma, comprising administering to said animal a therapeutically effective amount of a 4-pyridylmethyl-phthalazine derivative. | 2009-09-24 |
20090239873 | Phenyl-piperazine derivatives as modulators of muscarinic receptors - The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases. | 2009-09-24 |
20090239874 | Pyrido[3,2-e]pyrazines, their use as inhibitors of phospohodiesterase 10, and processes for preparing them - The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical preparations which comprise these compounds and to the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 10, as active compounds for treating diseases of mammals including a human which can be influenced by using the compounds according to the invention to inhibit phosphodiesterase 10 activity in the central nervous system. More particularly, the invention relates to the treatment of neurologic and psychiatric disorders, for example psychosis and disorders comprising cognitive deficits as symptoms. | 2009-09-24 |
20090239875 | Protection of ferulic acid and/or tetramethylpyrazine against retinal ischaemia, glaucoma and siderosis oculi - A method for preventing and/or treating ischaemic and/or iron-related retinal or brain disorders comprising administering an effective amount of ferulic acid (FA), tetramethylpyrazine (TMP) or their pharmaceutically acceptable salt, ester, solvate, hydrate, analogs, metabolite, enantiomer, isomer, tautomer, amide, derivative or prodrug to a subject. The former diseases comprise retinal ischemia, glaucoma as well as brain ischaemia (i.e. stroke, infarction typed). The latter ones comprise age-related macular degeneration, intraocular hemorrhage, siderosis oculi (due to retained intraocular iron), oxidative stress of the retina as well as brain hemorrhage (stroke, hemorrhagic type) or Alzheimer disease. Clinically, FA alone or in combination of TMP can be administered systemically, orally, intravitreously, topically (in form of eyedrops), as well as other routes such as periocular, subconjunctival, and intracamera. | 2009-09-24 |
20090239876 | Substituted 4-Hydroxypyrimidine-5-Carboxamides - The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions. | 2009-09-24 |
20090239877 | NOVEL 1,2,4-TRIAZOLE DERIVATIVES AND PROCESS OF MANUFACTURING THEREOF - The invention provides 1,2,4-triazole compounds, compositions containing those compounds, methods of treating diseases and/or disorders with those compounds and processes of manufacturing 1,2,4-triazole compounds. | 2009-09-24 |
20090239878 | COMBINATIONS OF (A) AN ATP-COMPETITIVE INHIBITOR OF C-ABL KINASE ACTIVITY WITH (B) TWO OR MORE OTHER ANTINEOPLASTIC AGENTS - The invention relates to combinations of (a) an ATP-competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease | 2009-09-24 |
20090239879 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES - The invention relates to N-phenyl-2-pyrimidine-amine derivatives derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans. | 2009-09-24 |
20090239880 | COMBINATIONS OF MONOAMINE REUPTAKE INHIBITORS AND POTASSIUM CHANNEL ACTIVATORS - This invention provides pharmaceutical compositions comprising therapeutically effective amounts of a monoamine reuptake inhibitor and an SK inhibitor. In another aspect the invention provides novel benzoimidazole derivatives for use according to the invention. | 2009-09-24 |
20090239881 | Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments - The invention is directed to a combination of flibanserin or a pharmaceutically acceptable derivative thereof and caffeine or a pharmaceutically acceptable derivative thereof for the treatment of Sexual Disorders in humans, particularly women. | 2009-09-24 |
20090239882 | Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity - A compound of formula (I), or a pharmaceutically acceptable salt, or solvate thereof; and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders. | 2009-09-24 |
20090239883 | Treatment of Pulmonary Hypertension - This invention relates to the use of certain cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitors, including in particular the compound sildenafil, for the treatment of pulmonary hypertension. | 2009-09-24 |
20090239884 | Methods of Treating Inflammation - The invention features compositions and methods for treating inflammation and other immune-related disorders. | 2009-09-24 |
20090239885 | Inhibitors of nucleoside phoshorylases and nucleosidases - The present invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine nucleosidases (MTAN) and/or nucleoside hydrolases (NH). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds. | 2009-09-24 |
20090239886 | Substituted xanthine derivatives - This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial. | 2009-09-24 |
20090239887 | Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers - A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (−)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner. | 2009-09-24 |
20090239888 | Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation - Compositions and uses of mGluR | 2009-09-24 |
20090239889 | Spiroindolinone Derivatives - There are provided compounds of the general formulas | 2009-09-24 |
20090239890 | SPIRO SUBSTITUTED CYCLOPROPANE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS - A compound of the Formula I: | 2009-09-24 |
20090239891 | Sustained Release Dosage Forms of Analgesic Medications - Parenteral extravascular administration of a composition containing an analgesic medication of low water solubility that is dissolved, suspended, or emulsified in a solvent system results in the deposition of the analgesic medication at the site of administration and provides a controlled release of the analgesic medication from the site and a prolonged analgesia that may persist for several days following administration. | 2009-09-24 |
20090239892 | PYRIDOMORPHINANS, PYRIDAZINOMORPHINANS AND USE THEREOF - Compounds represented by the formula: | 2009-09-24 |
20090239893 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN - A stereoselective process for preparing 7-[(E)-t-butyloxyiminomethyl]-camptothecin (also known as gimatecan) is herein disclosed. With the addition of further dissolution and precipitation steps carried out in appropriate different solvent mixtures, four new crystalline forms of gimatecan are also obtainable by using the same stereoselective process. | 2009-09-24 |
20090239894 | Stabilized aqueous solutions of ergoline compounds - The present invention relates to stabilized aqueous solutions of an ergoline compound of formula I | 2009-09-24 |
20090239895 | Novel 3-thia-10-aza-phenanthrene derivatives - The compounds of formula I | 2009-09-24 |
20090239896 | AZAINDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS - Indole and indole-related compounds, compositions and methods are disclosed. The compounds of the invention are useful as phospholipase inhibitors. The compounds and compositions of the invention are useful for treatment of phospholipase-related conditions, such as insulin-related, weight-related and/or cholesterol-related conditions in an animal subject. The compounds include azaindoles of the formula below [insert FIG. | 2009-09-24 |
20090239897 | NOVEL COMPOUNDS - Novel substituted 1,5,7-trisubstituted-1,8-napthyridin-2(1H)-one compounds; 1,5,7 trisubstituted-1,6-napthyridine-2-(1H)-one compounds and 1,5,7-trisubstituted quinoline-2(1H)-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy. | 2009-09-24 |
20090239898 | FURTHER THERAPEUTIC USE OF ZOLPIDEM - An imidazo[1,2-a] pyridine-3-acetamide such as zolpidem is useful in the treatment of a condition of the brain which has a lesion and exhibits diaschisis/dormant cells at the contralateral and other sites, more particularly trauma-induced injury, spinocerebellar ataxia, cerebellar or cerebral infarct and Ramsey-Hunt syndrome. | 2009-09-24 |
20090239899 | Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors - A compound of formula (I), or a pharmaceutical acceptable salt and/or solvate (including hydrate) thereof; | 2009-09-24 |
20090239900 | QUININE AND QUINIDINE SALTS, METHODS FOR MAKING THEM, AND PHARMACEUTICAL FORMULATIONS COMPRISING THEM - The present invention provides a combination of:
| 2009-09-24 |
20090239901 | METHOD AND COMPOSITIONS FOR TREATMENT OF CEREBRAL MALARIA - A method of treating inflammatory disorders, including cerebral malaria, by administration of modulators of α | 2009-09-24 |
20090239902 | QUININE DOSAGE FORMS AND METHODS OF USE THEREOF - Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed are methods of using quinine and informing a user of information, including potential adverse effects, the effect of food on quinine's pharmacokinetics, effect of dosing various strengths of quinine, effect of maximum plasma concentrations of quinine in a patient as it relates to adverse events, effects of deviating from the prescribed dosage, etc. | 2009-09-24 |
20090239903 | TETRAHYDROQUINOLINE ANALOGUES AS MUSCARINIC AGONISTS - The present invention relates to tetrahydroquinoline compounds as muscarinic receptor agonists; compositions comprising the same; methods of inhibiting an activity of a muscarinic receptor with said compounds; methods of treating a disease condition associated with a muscarinic receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds. | 2009-09-24 |
20090239904 | COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY - This invention provides compounds of formula I: | 2009-09-24 |
20090239905 | PIPERIDINES AND RELATED COMPOUNDS FOR THE TREATMENT OF DEMENTIA - Compounds of formula I: modulate the action of gamma secretase, and hence find use in treatment of Alzheimer's disease and related conditions. | 2009-09-24 |
20090239906 | ALKOXYALKYL-SUBSTITUTED CYCLIC KETOENOLS - The invention relates to new alkoxyalkyl-substituted cyclic ketoenols of the formula (I) | 2009-09-24 |
20090239907 | METHODS AND COMPOSITIONS FOR TREATING FISH DISEASES - Therapeutic and prophylactic treatments of aquatic species and aquatic diseases through the controlled introduction of a heterocyclic N-halamine into an aquatic habitat. | 2009-09-24 |
20090239908 | METHODS OF TREATING PSYCHOSIS AND SCHIZOPHRENIA BASED ON POLYMORPHISMS IN THE CNTF GENE - This invention relates to the use of the association between the 103 G>A polymorphism in the CNTF gene to determine antipsychotic treatment strategies in patients with psychotic disorders. | 2009-09-24 |
20090239909 | TREATMENT OF METABOLIC SYNDROME WITH LACTAMS - The present invention relates to the treatment of metabolic syndrome or disorders associated with metabolic syndrome comprising administering a compound of the invention. | 2009-09-24 |
20090239910 | Benzenesulfonamide Compounds and Their Use - The invention relates to azetidinyl, pyrrolidinyl, piperidinyl, and hexahydroazepinyl compounds of Formula I and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein R | 2009-09-24 |
20090239911 | CYCLOHEXYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 - The present invention discloses novel compounds of Formula I: having 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11β-HSD type 1 activity. | 2009-09-24 |
20090239912 | CONCENTRATED, NON-FOAMING SOLUTION OF QUATERNARY AMMONIUM COMPOUNDS AND METHODS OF USE - A concentrated quaternary ammonium compound (QAC) solution comprising a QAC with a concentration from greater than about 10% by weight and at least one solubility enhancing agent, such as an alcohol, is disclosed. A diluted QAC solution is used to contact food products to prevent microbial growth on the food products from a broad spectrum of foodborne microbial contamination. A method of contacting the food products with the dilute QAC for an application time of at least 0.1 second is disclosed. The foods that can be treated by this method are meat and meat products, seafood, vegetables, fruit, dairy products, pet foods and snacks, and any other food that can be treated and still retain its appearance and texture. One of the treatment methods is spraying and misting the QAC solutions on the food products for an application time of at least 0.1 second to prevent broad spectrum foodborne microbial contamination. | 2009-09-24 |
20090239913 | Process for the treatment and prevention of diseases caused by fungi - The subject invention is directed to the treatment of infections caused by fungi which are resistant to standard antifungal drugs such as fluconazole. The treatment method involves administering to the sufferer an effective amount of an agent that suppresses the activity of the fungal (H+)-ATPase pump (Pma1p). Such agents may take the form of: a) 2-phenyl-1,2-benzisoselenazol-3(2H)-one, commonly referred to as ebselen and depicted by Formula I, or b) 2-phenyl-1,2-benzisoselenazol-3(2H)-one 1-oxide, commonly referred to as ebselen se-oxide and depicted by Formula II, or pharmaceutically acceptable salts thereof. Opportunistic fungal infections include those which are systemic and those which are superficial and are caused by species of fungi belonging to the genus | 2009-09-24 |
20090239914 | Phosphorus binder for treatment of renal disease - The present invention relates to oral compositions which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The dietary supplements and pharmaceutical products and methods of the present invention are particularly useful in the treatment of hyperphosphatemia of chronic uremia and reducing serum phosphorus levels in patients requiring such therapy. | 2009-09-24 |
20090239915 | Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals - The present invention relates to derivatives of 2-phenyl-benzimidazoles of the formula I, | 2009-09-24 |
20090239916 | NOVEL DRUG DISCOVERY TARGET AND MEDICINE ACTING ON THE SAME - The present invention provides a pharmaceutical composition comprising as an active ingredient a compound that specifically binds to MFP-2 or a functional fragment thereof and a screening method for the compound; the compound and a pharmaceutical composition comprising the same are highly useful as anti-inflammatory agents and anti-allergic agents. | 2009-09-24 |
20090239917 | Heterocyclic Cycloalkyl Compounds, a Process for their Preparation and Pharmaceutical Compositions Containing Them - Compounds of formula (I): | 2009-09-24 |
20090239918 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF - The invention provides methods for treating pain in mammals. In particular, the invention provides well-defined aminoimidazolines, aminothiazolines, and aminooxazolines and pharmaceutical compositions thereof to treat pain. | 2009-09-24 |
20090239919 | Glutamate receptor modulators and therapeutic agents - The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds. Diseases and disorders contemplated include, inter alia, diseases and disorders of the central nervous system, the peripheral nervous system, the gastrointestinal system, the circulatory system, skin, retina, brain, heart, and lungs. | 2009-09-24 |
20090239920 | PHARMACEUTICAL FORMULATIONS OF AN ANHYDRATE CRYSTAL FORM OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL - The present invention is directed to pharmaceutical formulations of an anhydrate crystal form of an estrogen receptor modulator, and pharmaceutical compositions and preparative processes thereof. | 2009-09-24 |
20090239921 | METHODS FOR TREATING NEOPLASMS WITH DERIVATIVES OF 4,5,6,7-TETRABROMOBENZIMIDAZOLE - A pharmaceutical composition exhibiting an anti-neoplastic activity, comprising: a pharmaceutically-effective amount of a compound of Formula 1 | 2009-09-24 |
20090239922 | Kinesin inhibitors as cancer therapeutics - The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein. | 2009-09-24 |
20090239923 | CONCENTRATED AQUEOUS AND/OR ETHANOLIC SOLUTION OF 4-METHYLPYRAZOLE (FOMEPIZOLE) - A composition of matter comprising fomepizole and water wherein the content of water is about 3% to about 40% by weight, and methods of making fomepizole solutions effective to reduce the freezing point of pure fomepizole to less than about 18° C. | 2009-09-24 |